Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Post by dt_coreon Jul 28, 2011 10:11pm
163 Views
Post# 18885691

CNH Global Q2 blows past Wall Street

CNH Global Q2 blows past Wall Street

(Reuters) - Farm equipment maker CNH Global N.V. (CNH.N) posted market-topping results for the ninth straight quarter and raised revenue growth outlook for the year, helped by higher crop prices, sending its shares up 10 percent.

High food prices are expected to lift farm profits to record levels this year despite higher costs for seeds and fertilizer. That is leading farmers to invest in equipment to boost productivity.

CNH Global -- the world's second largest maker of farm equipment after Deere & Co (DE.N) -- raised its full-year revenue growth outlook to 15-20 percent, up from its previous outlook of 10 percent.

Morning Star analyst Adam Fleck said the company has gained a lot of market share in places like North America. "Its new products and strategies are paying off," he said.

CNH's parent Fiat Industrial SpA (FI.MI) raised 2011 targets earlier on Monday after higher second-quarter sales helped the truck and heavy equipment maker beat profit forecast by around a fifth.

CNH's second-quarter net income was $320 million, or $1.33 per share, up from $144 million, or 60 cents a share, a year ago. Net sales grew 24 percent to $4.88 billion.

Analysts, on average, were expecting earnings of 99 cents a share on revenue of $4.52 billion, according to Thomson Reuters I/B/E/S.

Bullboard Posts